Predictors of adverse drug reactions associated with ribavirin in direct‐acting antiviral therapies for chronic hepatitis C-Reference-Cited by-同舟云学术

Predictors of adverse drug reactions associated with ribavirin in direct‐acting antiviral therapies for chronic hepatitis C

Published:2019-11-06 Issue:12 Volume:28 Page:1601-1608
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Cursino Camille Nigri¹^ORCID,Monteiro Priscilla Garcia de Oliveira¹^ORCID,Duarte Gabriel da Silva¹^ORCID,Vieira Tassita Bezz Quintanilha²^ORCID,Crisante Verônica de Carvalho²^ORCID,Giordani Fabíola³^ORCID,Xavier Analúcia Rampazzo²^ORCID,Almeida Renan Moritz Varnier Rodrigues⁴^ORCID,Calil‐Elias Sabrina¹^ORCID

Affiliation:

1. Mestrado Profissional em Administração e Gestão da Assistência Farmacêutica, Faculdade de FarmáciaUniversidade Federal Fluminense Rio de Janeiro Brazil

2. Faculdade de FarmáciaUniversidade Federal Fluminense Rio de Janeiro Brazil

3. Faculdade de MedicinaUniversidade Federal Fluminense Rio de Janeiro Brazil

4. PEB/Instituto Alberto Luiz Coimbra de Pós‐graduação e Pesquisa de Engenharia, Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.4904

Reference34 articles.

1. 25 years of Hepatitis C

2. World Health Organization.Global Hepatitis Report.2017.

3. Hepatitis C vaccine

4. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development;Bailey JR;Gastroenterology,2018

5. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross‐sectional study;Pereira LM;BMC Infectious Disease.,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase;Expert Opinion on Investigational Drugs;2024-01-02